Skandinaviska Enskilda Banken AB publ Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,892 shares of the biopharmaceutical company’s stock after buying an additional 12,339 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.08% of Alnylam Pharmaceuticals worth $25,967,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in ALNY. Capital International Investors boosted its position in Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares during the period. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares during the period. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $18,886,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, September 9th. Finally, Leerink Partners lifted their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $279.14.

Alnylam Pharmaceuticals Stock Down 0.9 %

Shares of ALNY stock opened at $273.88 on Friday. The company has a market cap of $34.64 billion, a P/E ratio of -102.19 and a beta of 0.38. The business has a 50 day moving average of $260.11 and a two-hundred day moving average of $198.73. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period last year, the business posted ($2.21) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.